High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies

2009 ◽  
Vol 124 (2) ◽  
pp. 333-338 ◽  
Author(s):  
Nicola Tinari ◽  
Rossano Lattanzio ◽  
Patrizia Querzoli ◽  
Clara Natoli ◽  
Antonino Grassadonia ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
High Expression ◽  
Breast Cancer Patients ◽  
Poor Survival ◽  
Node Negative ◽  
Node Negative Breast Cancer ◽  
Systemic Therapies

K167: is it a prognostic index in node negative breast cancer patients?

2001 ◽  
Vol 37 ◽  
pp. S121
Author(s):  
F. Valcamonico ◽  
G. Grigolato ◽  
F. Donato ◽  
V.D. Ferrari ◽  
E. Simoncini ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Prognostic Index ◽  
Breast Cancer Patients ◽  
Node Negative ◽  
Node Negative Breast Cancer

OncotypeDX Recurrence Score Does Not Predict Nodal Burden in Clinically Node Negative Breast Cancer Patients

2018 ◽  
Vol 26 (3) ◽  
pp. 815-820 ◽  
Author(s):  
S. E. Tevis ◽  
R. Bassett ◽  
I. Bedrosian ◽  
C. H. Barcenas ◽  
D. M. Black ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Recurrence Score ◽  
Breast Cancer Patients ◽  
Node Negative ◽  
Node Negative Breast Cancer ◽  
Nodal Burden

scholarly journals Arm lymphoedema and upper limb impairments in sentinel node-negative breast cancer patients: A one year follow-up study

The Breast ◽  
2016 ◽  
Vol 29 ◽  
pp. 102-108 ◽  
Author(s):  
An De Groef ◽  
Marijke Van Kampen ◽  
Elena Tieto ◽  
Petra Schönweger ◽  
Marie-Rose Christiaens ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Upper Limb ◽  
Breast Cancer Patients ◽  
Node Negative ◽  
Follow Up Study ◽  
Node Negative Breast Cancer ◽  
Arm Lymphoedema ◽  
One Year

scholarly journals PV-0235: Is there a subset who benefits from PMRT in node-negative breast cancer patients?

2017 ◽  
Vol 123 ◽  
pp. S118
Author(s):  
H.J. Park ◽  
K. Shin ◽  
J. Kim ◽  
S. Ahn ◽  
S. Kim ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Node Negative ◽  
Node Negative Breast Cancer

183 A DNA signature to identify high-risk small node-negative breast cancer patients

2010 ◽  
Vol 8 (3) ◽  
pp. 111-112 ◽  
Author(s):  
E. Gravier ◽  
G. Pierron ◽  
A. Vincent-Salomon ◽  
N. Gruel ◽  
V. Raynal ◽  
...  
Keyword(s):  
Breast Cancer ◽  
High Risk ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Node Negative ◽  
Node Negative Breast Cancer

scholarly journals Tumor-Biological Factors Upa and PAI-1 as Stratification Criteria of a Multicenter Adjuvant Chemotherapy Trial in Node-Negative Breast Cancer

2000 ◽  
Vol 15 (1) ◽  
pp. 73-78 ◽  
Author(s):  
A. Prechtl ◽  
N. Harbeck ◽  
C. Thomssen ◽  
C. Meisner ◽  
M. Braun ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Plasminogen Activator ◽  
Systemic Therapy ◽  
Axillary Node ◽  
Breast Cancer Patients ◽  
Node Negative ◽  
Node Negative Breast Cancer ◽  
Pai 1

In axillary node-negative primary breast cancer, 70% of the patients will be cured by locoregional treatment alone. Therefore, adjuvant systemic therapy is only needed for those 30% of node-negative patients who will relapse after primary therapy and eventually die of metastases. Traditional histomorphological and clinical factors do not provide sufficient information to allow accurate risk group assessment in order to identify node-negative patients who might benefit from adjuvant systemic therapy. In the last decade various groups have reported a strong and statistically independent prognostic impact of the serine protease uPA (urokinase-type plasminogen activator) and its inhibitor PAI-1 (plasminogen activator inhibitor type 1) in node-negative breast cancer patients. Based on these data, a prospective multicenter therapy trial in node-negative breast cancer patients was started in Germany in June 1993, supported by the German Research Association (DFG). Axillary node-negative breast cancer patients with high levels of either or both proteolytic factors in the tumor tissue were randomized to adjuvant CMF chemotherapy versus observation only. Recruitment was continued until the end of 1998, by which time 684 patients had been enrolled. Since then, patients have been followed up in order to assess the value of uPA and PAI-1 determination as an adequate selection criterion for adjuvant chemotherapy in node-negative breast cancer patients. This paper reports on the rationale and design of this prospective multicenter clinical trial, which may have an impact on future policies in prognosis-oriented treatment strategies.

scholarly journals Possible benefits from post-mastectomy radiotherapy in node-negative breast cancer patients: a multicenter analysis in Korea (KROG 14-22)

Oncotarget ◽  
2017 ◽  
Vol 8 (35) ◽  
pp. 59800-59809 ◽  
Author(s):  
Hae Jin Park ◽  
Kyung Hwan Shin ◽  
Jin Ho Kim ◽  
Seung Do Ahn ◽  
Su Ssan Kim ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Node Negative ◽  
Node Negative Breast Cancer ◽  
Multicenter Analysis
Sign in / Sign up

Export Citation Format

Share Document